HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required) | RFA NS 22 037

Opportunity Information: Apply for RFA NS 22 037

The HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required) funding opportunity (RFA-NS-22-037) is an NIH grant solicitation aimed at reducing persistent inequities in pain care and pain outcomes. It focuses on NIH-designated health disparity populations (HDPs), meaning groups that disproportionately experience negative health outcomes and barriers to high-quality care. The central idea is to move beyond one-size-fits-all approaches by supporting interventions that are culturally appropriate, feasible in real-world settings, and built to address the structural and contextual factors that often drive worse outcomes in these communities. The opportunity sits within NIH's broader HEAL (Helping to End Addiction Long-term) Initiative, which emphasizes evidence-based solutions to pain and opioid-related harms.

The announcement supports projects that either (1) develop, test, and implement new multi-level interventions or (2) adapt and rigorously test existing interventions for efficacy and real-world effectiveness in HDP settings. "Multi-level" generally signals that NIH is interested in approaches that work across more than one layer of influence, such as the patient level (self-management skills, behavior change, treatment adherence), the clinician level (training, decision support, stigma reduction), the clinic or health system level (care pathways, referral processes, integrated services), and the community level (peer navigation, community health workers, partnerships with local organizations). A key expectation is that interventions are not only innovative, but also practical to deliver where people actually receive care, including safety-net clinics, community-based organizations, tribal health systems, and other under-resourced environments.

In terms of desired outcomes, NIH is looking for measurable improvements in pain and pain-related symptoms along with better patient-centered outcomes. This includes reductions in pain intensity and interference, improvements in function and quality of life, and higher patient satisfaction with care. The opportunity explicitly values outcomes that matter to patients and communities, not just clinical metrics, which aligns with a health equity emphasis where trust, access, continuity, and perceived quality often shape whether an intervention will be accepted and sustained.

Projects that address chronic pain plus at least one major comorbid condition are described as the highest priority. The comorbidities emphasized include opioid use disorder (OUD), mental health disorders, and/or other chronic health conditions. This reflects the reality that chronic pain commonly overlaps with depression, anxiety, PTSD, substance use, and chronic illnesses such as diabetes or cardiovascular disease, and that these intersections can compound disability and inequities. NIH is signaling that strong applications will treat pain in context, using integrated or coordinated care models that acknowledge how comorbidities influence pain outcomes, treatment engagement, and risk (including overdose risk when opioids are involved).

The funding mechanism is the R61/R33 phased innovation award, and a clinical trial is required. In practice, this structure typically means an initial R61 phase used to establish feasibility and readiness (for example, refining the intervention, confirming recruitment and retention strategies, piloting workflows, and meeting pre-specified milestones), followed by an R33 phase that supports a larger-scale test of efficacy and/or effectiveness. The milestone-driven transition is important: applicants generally need to propose clear, objective "go/no-go" criteria and a realistic plan for progressing from early-stage work into a more definitive clinical trial that evaluates outcomes.

Eligibility is broad and includes many organizations positioned to conduct community-engaged clinical research. Eligible applicants listed include state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The announcement also highlights additional applicant types that NIH specifically welcomes, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, tribal governments that are not federally recognized, and U.S. territories or possessions. At the same time, it clearly restricts foreign involvement: non-U.S. entities and foreign institutions are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components as defined by NIH policy are not allowed.

Administratively, the opportunity is categorized as a discretionary grant under activity areas spanning education, health, income security, and social services, reflecting the multi-sector nature of health equity work. The agency is the National Institutes of Health, and the original closing date listed is March 22, 2022 (created January 20, 2022). Multiple CFDA numbers are associated with the announcement (including 93.121, 93.213, 93.273, 93.279, 93.307, 93.313, 93.350, 93.361, 93.393, 93.846, 93.853, 93.865, and 93.866), indicating participation across NIH institutes and programs that touch pain, neuroscience, mental health, substance use, and related health domains.

Overall, this FOA is designed for teams that can combine rigorous clinical trial methods with culturally grounded, community-engaged implementation strategies. Competitive projects are likely to be those that show a strong understanding of the specific barriers faced by the targeted HDP group, partner credibly with the communities involved, select outcomes that reflect both symptom reduction and meaningful life improvements, and build an intervention that can realistically be sustained and scaled in the settings where inequities are most pronounced.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.279, 93.307, 93.313, 93.350, 93.361, 93.393, 93.846, 93.853, 93.865, 93.866.
• This funding opportunity was created on 2022-01-20.
• Applicants must submit their applications by 2022-03-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 22 037

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: